Fluconazole

Cerebral Cryptococcosis, Candidemia, Coccidioidomycosis + 22 more
Treatment
24 FDA approvals
20 Active Studies for Fluconazole

What is Fluconazole

FluconazoleThe Generic name of this drug
Treatment SummaryFluconazole, also known as Diflucan, is an antifungal medication used to treat fungal infections in different parts of the body. It was approved by the FDA in 1990 and belongs to the same drug family as ketoconazole and itraconazole. Fluconazole offers the advantage of being taken orally and has a low risk of side effects. It is very effective and is often prescribed as a single dose to treat vaginal yeast infections.
Diflucanis the brand name
image of different drug pills on a surface
Fluconazole Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Diflucan
Fluconazole
1990
379

Approved as Treatment by the FDA

Fluconazole, also called Diflucan, is approved by the FDA for 24 uses which include Candida pneumonia and Candida (fungus) .
Candida pneumonia
Candida (fungus)
Vaginal Candidiasis
Used to treat Vaginal Candidiasis in combination with Miconazole
Pruritus
Used to treat Pruritus in combination with Miconazole
Candidiasis
Systemic candidiasis
Meningitis, Cryptococcal
Coccidioidomycosis
Oropharyngeal Candidiasis
Candida urinary tract infection
Itching
Used to treat Pruritus in combination with Miconazole
Candidiasis, Vulvovaginal
Used to treat Vaginal Candidiasis in combination with Miconazole
Coccidioidomycosis
Urinary tract infection
Candida (fungus)
Peritonitis
Esophageal Candidiasis
Cerebral Cryptococcosis
Yeast Infection
Bone marrow transplant, cytotoxic chemotherapy
Candidemia
Bone Marrow Transplantation
Candidiasis
prophylaxis of Candida Infections

Effectiveness

How Fluconazole Affects PatientsFluconazole is a medication used to treat fungal infections caused by Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, and Cryptococcus neoformans. It works by blocking the growth and spread of fungi by interfering with cell wall synthesis and cell adhesion. However, some strains of these fungi have become resistant to fluconazole, which is why it is important to do susceptibility tests before taking the medication. While there have been concerns that fluconazole may affect human hormones, studies have not found any significant effects when taking up to 400 mg
How Fluconazole works in the bodyFluconazole is a drug that interferes with the growth of fungi. It does this by blocking an enzyme that helps create an important part of the fungal cell wall. When this enzyme is blocked, the fungi can't build the cell wall and so it can't grow. Some fungi have developed resistance to this drug, either by changing the amount of the enzyme or by changing the way it works.

When to interrupt dosage

The proposed measure of Fluconazole is contingent upon the diagnosed condition, including Candida (fungus), Candida intertrigo and Bone Marrow Transplantation. The dosage can be located in the table beneath, predicated on the technique of delivery (e.g. Topical or Powder, for solution).
Condition
Dosage
Administration
Solid Organ Transplant
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Candidiasis
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Candidiasis, Vulvovaginal
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Urinary tract infection
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Communicable Diseases
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Yeast Infection
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Bone Marrow Transplantation
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Oropharyngeal Candidiasis
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Esophageal Candidiasis
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Candidemia
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Coccidioidomycosis
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Candida pneumonia
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Pneumonia
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Candida (fungus)
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Candida intertrigo
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Coccidioidomycosis
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
prophylaxis of moderate Pneumocystis pneumonia
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Itching
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
prophylaxis of Candida Infections
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical
Candida (fungus)
, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution, Solution - Intravenous, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Topical, Solution - Topical, Capsule; Cream - Oral; Topical

Warnings

Fluconazole Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Fluconazole may interact with Pulse Frequency
There are 20 known major drug interactions with Fluconazole.
Common Fluconazole Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Fluconazole.
Abrocitinib
Major
The metabolism of Abrocitinib can be decreased when combined with Fluconazole.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Fluconazole.
Acetylsalicylic acid
Major
The metabolism of Acetylsalicylic acid can be decreased when combined with Fluconazole.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Fluconazole.
Fluconazole Toxicity & Overdose RiskThe toxic dose of fluconazole for rats is 1271 mg/kg. Overdosing on fluconazole may cause hallucinations, paranoia, and other stomach related issues. A doctor may recommend flushing out the stomach or dialysis if the drug was taken less than 4 hours prior. People with existing liver issues should be careful when taking fluconazole, as it may worsen the condition. Animal studies have not shown any links to cancer or mutation, but pregnant women should be aware of the potential side effects before taking the drug. Fluconazole is secreted in breastmilk, so caution should be taken when
image of a doctor in a lab doing drug, clinical research

Fluconazole Novel Uses: Which Conditions Have a Clinical Trial Featuring Fluconazole?

37 active trials are currently assessing the utility of Fluconazole in ameliorating Urinary tract infection, Cerebral Cryptococcosis and Coccidioidomycosis.
Condition
Clinical Trials
Trial Phases
prophylaxis of moderate Pneumocystis pneumonia
0 Actively Recruiting
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
Urinary tract infection
0 Actively Recruiting
Candida (fungus)
0 Actively Recruiting
Pneumonia
0 Actively Recruiting
Bone marrow transplant, cytotoxic chemotherapy
0 Actively Recruiting
Candida (fungus)
0 Actively Recruiting
Peritonitis
0 Actively Recruiting
Cerebral Cryptococcosis
1 Actively Recruiting
Phase 2, Phase 3
Candida intertrigo
0 Actively Recruiting
Oropharyngeal Candidiasis
0 Actively Recruiting
Bone Marrow Transplantation
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Candidemia
4 Actively Recruiting
Phase 3, Phase 2
Candida pneumonia
0 Actively Recruiting
Esophageal Candidiasis
0 Actively Recruiting
prophylaxis of Candida Infections
0 Actively Recruiting
Yeast Infection
0 Actively Recruiting
Itching
2 Actively Recruiting
Phase 3, Not Applicable
Candidiasis
0 Actively Recruiting

Fluconazole Reviews: What are patients saying about Fluconazole?

5Patient Review
8/16/2022
Fluconazole for Candida Species Yeast Infection of Abdominal Cavity Lining
I don't love the taste, but it's not so bad that I can't get it down. Once you do, this treatment is very effective and doesn't require multiple doses or creams.
4.7Patient Review
10/21/2022
Fluconazole for Candida Fungus Infection of Mouth, Skin, Nails or Vagina
I completely understand why people might have negative things to say about this treatment, as yeast infections are really awful. However, I found that this pill worked wonders for me and cleared up the infection within a few days.
4.3Patient Review
5/6/2022
Fluconazole for Candida Species Yeast Infection of Abdominal Cavity Lining
The cheaper, store-brand options didn't work as well for me. Stick to the name brand if you want results.
3.3Patient Review
12/17/2021
Fluconazole for Thrush
Worked quickly, but I had really bad nausea and vomiting the next night.
3.3Patient Review
5/26/2022
Fluconazole for Candida Species Yeast Infection of Abdominal Cavity Lining
I had a rash all over my body.
3Patient Review
1/12/2021
Fluconazole for Ringworm of Scalp
Not a long-term solution, but it helped me in the short term.
2.3Patient Review
11/29/2021
Fluconazole for Candida Species Yeast Infection of Abdominal Cavity Lining
Unfortunately, I had a lot of negative side effects from this medication including stomach pains and acid reflux. Gas was also an issue. Definitely would not recommend and still experiencing problems even after 5 days have passed.
2Patient Review
10/27/2021
Fluconazole for Yeast Infection of Vagina and Vulva
I had some really unfortunate side effects after taking this medication- my heart was racing, I felt dizzy and nauseous, and my stomach was in so much pain. This was all after just the first dose of 150mg. I definitely won't be taking this again.
1.3Patient Review
1/2/2021
Fluconazole for Scattered Infection caused by Coccidioides Fungus
These pills have an incredibly unpleasant taste, to the point where I've gagged or even thrown up trying to take them. The only way I can get them down is by taking them with egg nog from October to February.
1.3Patient Review
6/4/2021
Fluconazole for Fungal Infection of the Skin with Yellow Patches
The only reason this medicine has such a high rating is because it's easy to take as a pill. I took 300mg for Tinea versicolor and have been incredibly sick since: dizzy, weak, with diarrhea and stomach pain for the last six days. I was supposed to take a second dose but there's no way I'm taking that pill again!
1Patient Review
9/2/2021
Fluconazole for Thrush
I had a really negative reaction to this treatment. I would urge anyone considering it to read reviews carefully and weigh the pros and cons before making a decision.
1Patient Review
6/16/2022
Fluconazole for Thrush
Do not use this medication! I experienced chest tightness, difficulty breathing, and high blood pressure after only taking two pills. It's been six days now and I'm still feeling the effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fluconazole

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does it take for the fluconazole to work?

"Fluconazole is usually prescribed as a single 150 mg dose for mild, uncomplicated infections. Symptoms usually improve within one to three days."

Answered by AI

What is fluconazole used to treat?

"Fluconazole is an antifungal medication used to treat fungal infections caused by different types of fungi, the most common being a yeast called candida."

Answered by AI

What happens to your body when you take fluconazole?

"Side effects may increase when taking fluconazole with pain drugs such as methadone or fentanyl. These increased side effects can include slower breathing, confusion, and drowsiness."

Answered by AI

Does fluconazole have side effects?

"medical emergency"

Answered by AI

Clinical Trials for Fluconazole

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Fluconazole clinical trials? We made a collection of clinical trials featuring Fluconazole, we think they might fit your search criteria.Go to Trials
Have you considered Fluconazole clinical trials? We made a collection of clinical trials featuring Fluconazole, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Fluconazole clinical trials? We made a collection of clinical trials featuring Fluconazole, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security